Business strategy in drug development


Latest Research and Reviews

  • Research |

    The success of mechanism-based drug discovery depends on the definition of the drug target, but targets are often poorly defined in the literature. Here, Overington and colleagues present a comprehensive map of the molecular targets of approved drugs, and explore aspects including the footprint of target classes across disease areas, the success of privileged target families and drug target orthologues across standard model organisms.

    • Rita Santos
    • , Oleg Ursu
    • , Anna Gaulton
    • , A. Patrícia Bento
    • , Ramesh S. Donadi
    • , Cristian G. Bologa
    • , Anneli Karlsson
    • , Bissan Al-Lazikani
    • , Anne Hersey
    • , Tudor I. Oprea
    •  & John P. Overington
  • Reviews |

    Chorus is a small, operationally independent organization within Eli Lilly and Company that specializes in drug development from candidate selection through to clinical proof of concept. Here, we describe its development philosophy, organizational structure, operational model and results in the decade since it was established, which indicate substantial productivity improvements in both time and cost compared to traditional drug development approaches.

    • Paul K. Owens
    • , Eyas Raddad
    • , Jeffrey W. Miller
    • , John R. Stille
    • , Kenneth G. Olovich
    • , Neil V. Smith
    • , Rosie S. Jones
    •  & Joel C. Scherer
  • Reviews |

    Pangalos and colleagues discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. They present a framework to guide research and development teams based on the five most important technical determinants of project success and pipeline quality: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor — the right culture — is also crucial in encouraging effective decision-making.

    • David Cook
    • , Dearg Brown
    • , Robert Alexander
    • , Ruth March
    • , Paul Morgan
    • , Gemma Satterthwaite
    •  & Menelas N. Pangalos
  • Reviews |

    IBD is associated with a young age at onset and normal life expectancy, which results in a lifetime accrual of disease-related costs. This Review discusses the economic impact of biologic therapy on direct costs of IBD, such as hospitalizations and surgeries, and indirect costs, such as those related to disability and loss of productivity.

    • Russell D. Cohen
  • Reviews |

    Third-party payers typically base their reimbursement decisions for a new drug predominantly on its health benefits relative to existing treatment options — termed relative efficacy (RE). Over the past decade, the role of payers has become more prominent, and drug developers increasingly need to satisfy the sometimes divergent needs of both regulators and payers to achieve market success. This article describes the political background to the RE debate and the challenges of RE assessment, and discusses the impact of RE on drug development.

    • Hans-Georg Eichler
    • , Brigitte Bloechl-Daum
    • , Eric Abadie
    • , David Barnett
    • , Franz König
    •  & Steven Pearson

News and Comment